First Light Asset Management LLC Acquires 276,485 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN)

First Light Asset Management LLC grew its position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) by 261.0% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 382,433 shares of the company’s stock after buying an additional 276,485 shares during the quarter. First Light Asset Management LLC owned 0.44% of Dyne Therapeutics worth $13,496,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently bought and sold shares of the company. Nisa Investment Advisors LLC boosted its holdings in Dyne Therapeutics by 904.1% in the 2nd quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock worth $26,000 after buying an additional 669 shares during the period. Amalgamated Bank increased its holdings in shares of Dyne Therapeutics by 39.9% in the 2nd quarter. Amalgamated Bank now owns 2,792 shares of the company’s stock worth $99,000 after buying an additional 796 shares during the last quarter. Public Employees Retirement Association of Colorado purchased a new stake in Dyne Therapeutics during the second quarter valued at approximately $203,000. Ameritas Investment Partners Inc. lifted its position in Dyne Therapeutics by 28.0% in the first quarter. Ameritas Investment Partners Inc. now owns 5,896 shares of the company’s stock worth $167,000 after buying an additional 1,291 shares during the last quarter. Finally, Farallon Capital Management LLC bought a new stake in shares of Dyne Therapeutics in the 2nd quarter worth about $212,000. Institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Price Performance

DYN opened at $34.63 on Tuesday. Dyne Therapeutics, Inc. has a 12 month low of $6.40 and a 12 month high of $47.45. The business has a 50 day simple moving average of $40.89 and a 200-day simple moving average of $33.71. The stock has a market capitalization of $3.03 billion, a P/E ratio of -8.72 and a beta of 1.07.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.70) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.02. Research analysts anticipate that Dyne Therapeutics, Inc. will post -2.96 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have recently commented on DYN shares. Morgan Stanley upped their price target on shares of Dyne Therapeutics from $48.00 to $52.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. JPMorgan Chase & Co. lifted their price objective on shares of Dyne Therapeutics from $39.00 to $43.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 9th. HC Wainwright reaffirmed a “buy” rating and set a $55.00 target price on shares of Dyne Therapeutics in a research report on Wednesday, September 4th. StockNews.com cut shares of Dyne Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, September 16th. Finally, Guggenheim lifted their target price on Dyne Therapeutics from $45.00 to $50.00 and gave the stock a “buy” rating in a report on Thursday, August 15th. One investment analyst has rated the stock with a sell rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Dyne Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $51.40.

Insider Activity

In other news, CEO John Cox bought 32,000 shares of the firm’s stock in a transaction dated Wednesday, September 4th. The stock was bought at an average price of $33.04 per share, for a total transaction of $1,057,280.00. Following the transaction, the chief executive officer now owns 8,000 shares in the company, valued at $264,320. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. In other Dyne Therapeutics news, CEO John Cox bought 32,000 shares of the business’s stock in a transaction on Wednesday, September 4th. The shares were purchased at an average price of $33.04 per share, with a total value of $1,057,280.00. Following the purchase, the chief executive officer now directly owns 8,000 shares of the company’s stock, valued at $264,320. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Richard William Scalzo sold 1,390 shares of the company’s stock in a transaction that occurred on Wednesday, September 18th. The stock was sold at an average price of $34.55, for a total value of $48,024.50. Following the completion of the sale, the senior vice president now owns 98,568 shares of the company’s stock, valued at $3,405,524.40. The disclosure for this sale can be found here. Insiders sold 12,705 shares of company stock worth $437,701 over the last ninety days. Corporate insiders own 20.77% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.